Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer

Abstract

The invention provides a drug for postoperative recovery of the bladder cancer and a preparation method of the drug for postoperative recovery of the bladder cancer. The drug for postoperative recovery of the bladder cancer consists of an orally taken capsule and externally used infusion decoction, wherein the active ingredients of the orally taken capsule are prepared from the following raw materials in parts by weight: 4-8 parts of donkey-hide gelatin, 10-30 parts of ginseng, 15-25 parts of ganoderma lucidum, 3-6 parts of resina liquidamberis, 10-15 parts of lalang grass rhizome, 8-15 parts of tuber fleeceflower stems, 10-20 parts of longan pulp and 12-24 parts of polyporus umbellatus; the active ingredients of the externally-used infusion decoction are prepared from the following raw materials in parts by weight: 6-18 parts of common camptotheca fruits, 30-60 parts of jasminum elongatum, 9-18 parts of radix sophorae flavescentis, 30-60 parts of hedyotis diffusa, 16-30 parts of pseudo-ginseng and 6-12 parts of bufonis venenum. The drug for postoperative recovery of the bladder cancer disclosed by the invention has the functions of warm-reinforcing and conditioning a body by being orally taken, dissipating stasis and treating the cancer by being externally used and infused, can be internally and externally used to dissipate stasis and reinforce warm, and can be internally and externally used to strengthen vital qi to eliminate pathogenic factor. The drug for postoperative recovery of the bladder cancer disclosed by the invention can be used for effectively solving the problem that the postoperative recovery of the bladder cancer is difficult and the bladder cancer easily relapses.

Description

field of invention [0001] The invention relates to the field of traditional Chinese medicines, in particular to a medicine for treatment recovery after resection of bladder urothelial carcinoma. Background technique [0002] More than 80% of bladder cancer is bladder urothelial carcinoma, which refers to malignant tumors on the bladder mucosa. It accounts for the first incidence of genitourinary system tumors in my country, and its incidence is second only to prostate cancer in the West. bit. Bladder urothelial carcinoma Bladder cancer is divided into non-muscle-invasive urothelial carcinoma and muscle-invasive urothelial carcinoma, which can occur at any age, even in children. The incidence of bladder cancer in men is 3 to 4 times that of women . [0003] Most patients with non-muscle-invasive urothelial carcinoma undergo transurethral resection of bladder tumor, but about 70% of patients relapse after surgery. Most patients with muscle-invasive urothelial carcinoma are t...

AI Technical Summary

Problems solved by technology

The efficacy and side effects of western medicine infusion or chemotherapy are also unsatisfactory. For example, the recurrence rate of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin within five years is more than 50%, and the failure rate of repeated treatment for relapsed patients reaches More than 80%, and due to the large side effects, patients cannot adhere to the treatment, which affects the curative effect

Partial cystectomy also has the disadvantages of high risk and obvious side effects, and its effective rate is only 45%.

Moreover, after the operation, the patient will be weak and anemic for a long time, with uneasy pain, lack of energy, secondary hematuria, inflammation and even infection, and it is difficult or difficult to recover.